{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T14:38:07Z","timestamp":1771943887289,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,28]],"date-time":"2021-12-28T00:00:00Z","timestamp":1640649600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009752","name":"Futurum - Akademin f\u00f6r H\u00e4lsa och V\u00e5rd, Region J\u00f6nk\u00f6pings l\u00e4ns","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009752","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/j.ctarc.2021.100505","type":"journal-article","created":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T13:05:42Z","timestamp":1641042342000},"page":"100505","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Risk for relapse and death after adjuvant chemotherapy associated with SNPs in patients with breast cancer - A retrospective study."],"prefix":"10.1016","volume":"30","author":[{"given":"Delmy","family":"Oliva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bengt-\u00c5ke","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mats","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nongnit","family":"Lewin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Freddi","family":"Lewin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ctarc.2021.100505_bib0001","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s11670-012-0281-x","article-title":"Evaluation of treatment response for breast cancer: are we entering the era of \"biological complete remission\"?","volume":"24","author":"Bian","year":"2012","journal-title":"Chin J Cancer Res"},{"issue":"1","key":"10.1016\/j.ctarc.2021.100505_bib0002","doi-asserted-by":"crossref","first-page":"7648","DOI":"10.1038\/s41598-020-64523-1","article-title":"Effect of Ki-67 Expression Levels and Histological Grade on Breast Cancer Early Relapse in Patients with Different Immunohistochemical-based Subtypes","volume":"10","author":"Liang","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.ctarc.2021.100505_bib0003","unstructured":"Cancerfonden, Cancer i siffror 2013. 2013: www.cancerfonden.se. p. 64."},{"key":"10.1016\/j.ctarc.2021.100505_bib0004","unstructured":"Cancerfonden, Cancerfondensrapport 2018. 2018."},{"key":"10.1016\/j.ctarc.2021.100505_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ctro.2016.12.001","article-title":"Single nucleotide polymorphisms might influence chemotherapy induced nausea in women with breast cancer","volume":"2","author":"Oliva","year":"2017","journal-title":"Clinical and Translational Radiation Oncology"},{"key":"10.1016\/j.ctarc.2021.100505_bib0006","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/bs.acr.2018.04.017","article-title":"Side Effects in Cancer Therapy: Are Sphingolipids to Blame?","volume":"140","author":"Patel","year":"2018","journal-title":"Adv Cancer Res"},{"issue":"17","key":"10.1016\/j.ctarc.2021.100505_bib0007","doi-asserted-by":"crossref","first-page":"4425","DOI":"10.1158\/1078-0432.CCR-13-0753","article-title":"New strategies in personalized medicine for solid tumors: molecular markers and clinical trial designs","volume":"20","author":"Jurgensmeier","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.ctarc.2021.100505_bib0008","first-page":"3227","article-title":"Incidence of febrile neutropenia in early stage breast cancer patients receiving adjuvant FEC-D treatment","volume":"22","author":"Assi","year":"2014","journal-title":"Support Care Cancer"},{"issue":"2","key":"10.1016\/j.ctarc.2021.100505_bib0009","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11912-014-0426-9","article-title":"Immunotherapy for the treatment of breast cancer","volume":"17","author":"Ernst","year":"2015","journal-title":"Curr Oncol Rep"},{"issue":"1","key":"10.1016\/j.ctarc.2021.100505_bib0010","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s12955-017-0779-5","article-title":"Intensive follow-up for women with breast cancer: review of clinical, economic and patient's preference domains through evidence to decision framework","volume":"15","author":"Lafranconi","year":"2017","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"10.1016\/j.ctarc.2021.100505_bib0011","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"Journal of the Royal Statistical Society. Series B (Methodological)"},{"issue":"11","key":"10.1016\/j.ctarc.2021.100505_bib0012","first-page":"1339","article-title":"Treatment of breast cancer","volume":"81","author":"Maughan","year":"2010","journal-title":"Am Fam Physician"},{"issue":"5","key":"10.1016\/j.ctarc.2021.100505_bib0013","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.breast.2014.06.004","article-title":"Current and future role of neoadjuvant therapy for breast cancer","volume":"23","author":"Untch","year":"2014","journal-title":"Breast"},{"issue":"19","key":"10.1016\/j.ctarc.2021.100505_bib0014","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","article-title":"20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years","volume":"377","author":"Pan","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ctarc.2021.100505_bib0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1009020","article-title":"Reflecting on 20 years of breast cancer modeling in CISNET: Recommendations for future cancer systems modeling efforts","volume":"17","author":"Trentham-Dietz","year":"2021","journal-title":"PLoS Comput Biol"},{"issue":"5","key":"10.1016\/j.ctarc.2021.100505_bib0016","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1093\/annonc\/mdz051","article-title":"European cancer mortality predictions for the year 2019 with focus on breast cancer","volume":"30","author":"Malvezzi","year":"2019","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ctarc.2021.100505_bib0017","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.annonc.2020.02.009","article-title":"European cancer mortality predictions for the year 2020 with a focus on prostate cancer","volume":"31","author":"Carioli","year":"2020","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ctarc.2021.100505_bib0018","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/2211738507666190122111224","article-title":"Drug Combinations in Breast Cancer Therapy","volume":"7","author":"Fisusi","year":"2019","journal-title":"Pharm Nanotechnol"},{"issue":"1","key":"10.1016\/j.ctarc.2021.100505_bib0019","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1080\/0284186X.2016.1237778","article-title":"Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013","volume":"56","author":"Ehinger","year":"2017","journal-title":"Acta Oncol"},{"issue":"3","key":"10.1016\/j.ctarc.2021.100505_bib0020","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12030735","article-title":"Treatment Strategies and Survival Outcomes in Breast Cancer","volume":"12","author":"Cheung","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctarc.2021.100505_bib0021","first-page":"119","article-title":"De-Escalating Treatment for Her2-Positive Early Breast Cancer","volume":"131","author":"Osborne","year":"2020","journal-title":"Trans Am Clin Climatol Assoc"},{"issue":"6","key":"10.1016\/j.ctarc.2021.100505_bib0022","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1159\/000511925","article-title":"Therapy Algorithms for the Diagnosis and Treatment of Patients with Early and Advanced Breast Cancer","volume":"15","author":"Schneeweiss","year":"2020","journal-title":"Breast Care (Basel)"},{"issue":"12","key":"10.1016\/j.ctarc.2021.100505_bib0023","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1080\/0284186X.2020.1830167","article-title":"Neoadjuvant breast cancer treatment response; tumor size evaluation through different conventional imaging modalities in the NeoDense study","volume":"59","author":"Skarping","year":"2020","journal-title":"Acta Oncol"},{"issue":"18","key":"10.1016\/j.ctarc.2021.100505_bib0024","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.2217\/pgs-2020-0106","article-title":"Impact of variants in ATP-binding cassette transporters on breast cancer treatment","volume":"21","author":"Xiao","year":"2020","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.ctarc.2021.100505_bib0025","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/bs.apcsb.2019.01.001","article-title":"Estrogen receptor signaling mechanisms","volume":"116","author":"Fuentes","year":"2019","journal-title":"Adv Protein Chem Struct Biol"},{"issue":"1","key":"10.1016\/j.ctarc.2021.100505_bib0026","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/bjc.2015.183","article-title":"Utility of pre-treatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as prognostic factors in breast cancer","volume":"113","author":"Koh","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctarc.2021.100505_bib0027","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.steroids.2014.06.012","article-title":"Estrogen receptors alpha (ERalpha) and beta (ERbeta): subtype-selective ligands and clinical potential","volume":"90","author":"Paterni","year":"2014","journal-title":"Steroids"},{"issue":"4","key":"10.1016\/j.ctarc.2021.100505_bib0028","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.beem.2015.04.008","article-title":"Estrogen receptor alpha and beta in health and disease","volume":"29","author":"Jia","year":"2015","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.ctarc.2021.100505_bib0029","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1152\/physrev.00024.2016","article-title":"Membrane and Nuclear Estrogen Receptor Alpha Actions: From Tissue Specificity to Medical Implications","volume":"97","author":"Arnal","year":"2017","journal-title":"Physiol Rev"},{"issue":"9","key":"10.1016\/j.ctarc.2021.100505_bib0030","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19092591","article-title":"Molecular Pathways of Estrogen Receptor Action","volume":"19","author":"Pakdel","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"14","key":"10.1016\/j.ctarc.2021.100505_bib0031","doi-asserted-by":"crossref","first-page":"23996","DOI":"10.18632\/oncotarget.15098","article-title":"Caspase-9: structure, mechanisms and clinical application","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctarc.2021.100505_bib0032","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.biopha.2017.08.045","article-title":"Berberine activates caspase-9\/cytochrome c-mediated apoptosis to suppress triple-negative breast cancer cells in vitro and in vivo","volume":"95","author":"Zhao","year":"2017","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"10.1016\/j.ctarc.2021.100505_bib0033","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1111\/jcmm.14047","article-title":"Disabled-1 is down-regulated in clinical breast cancer and regulates cell apoptosis through NF-kappaB\/Bcl-2\/caspase-9","volume":"23","author":"Cao","year":"2019","journal-title":"J Cell Mol Med"},{"issue":"4","key":"10.1016\/j.ctarc.2021.100505_bib0034","doi-asserted-by":"crossref","first-page":"521","DOI":"10.2174\/1871520617666171114094847","article-title":"Halilectin-3, a Lectin from the Marine Sponge Haliclona caerulea, Induces Apoptosis and Autophagy in Human Breast Cancer MCF7 Cells Through Caspase-9 Pathway and LC3-II Protein Expression","volume":"18","author":"do Nascimento-Neto","year":"2018","journal-title":"Anticancer Agents Med Chem"},{"issue":"2","key":"10.1016\/j.ctarc.2021.100505_bib0035","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0092-8674(02)00625-6","article-title":"Apoptosis: a link between cancer genetics and chemotherapy","volume":"108","author":"Johnstone","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.ctarc.2021.100505_bib0036","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.semcancer.2019.08.012","article-title":"Metastatic heterogeneity of breast cancer: Molecular mechanism and potential therapeutic targets","volume":"60","author":"Liang","year":"2020","journal-title":"Semin Cancer Biol"},{"issue":"2","key":"10.1016\/j.ctarc.2021.100505_bib0037","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/s41416-021-01328-7","article-title":"Breast cancer as an example of tumour heterogeneity and tumour cell plasticity during malignant progression","volume":"125","author":"Luond","year":"2021","journal-title":"Br J Cancer"},{"issue":"23","key":"10.1016\/j.ctarc.2021.100505_bib0038","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25235686","article-title":"Overview of New Treatments with Immunotherapy for Breast Cancer and a Proposal of a Combination Therapy","volume":"25","author":"Galvan Morales","year":"2020","journal-title":"Molecules"}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S246829422100201X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S246829422100201X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:20:43Z","timestamp":1762842043000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S246829422100201X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":38,"alternative-id":["S246829422100201X"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2021.100505","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk for relapse and death after adjuvant chemotherapy associated with SNPs in patients with breast cancer - A retrospective study.","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2021.100505","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100505"}}